| DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis J Bartkova, Z Hořejší, K Koed, A Krämer, F Tort, K Zieger, P Guldberg, ... Nature 434 (7035), 864-870, 2005 | 3234 | 2005 |
| Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease S Stein, MG Ott, S Schultze-Strasser, A Jauch, B Burwinkel, A Kinner, ... Nature medicine 16 (2), 198-204, 2010 | 922 | 2010 |
| Prediction of acute myeloid leukaemia risk in healthy individuals S Abelson, G Collord, SWK Ng, O Weissbrod, N Mendelson Cohen, ... Nature 559 (7714), 400-404, 2018 | 826 | 2018 |
| Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 … C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ... The lancet oncology 16 (16), 1691-1699, 2015 | 463 | 2015 |
| Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial JE Cortes, S Khaled, G Martinelli, AE Perl, S Ganguly, N Russell, ... The Lancet Oncology 20 (7), 984-997, 2019 | 461 | 2019 |
| Centrosome-associated Chk1 prevents premature activation of cyclin-B–Cdk1 kinase A Krämer, N Mailand, C Lukas, RG Syljuåsen, CJ Wilkinson, EA Nigg, ... Nature cell biology 6 (9), 884-891, 2004 | 413 | 2004 |
| Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial H Serve, U Krug, R Wagner, MC Sauerland, A Heinecke, U Brunnberg, ... Journal of Clinical Oncology 31 (25), 3110-3118, 2013 | 388 | 2013 |
| Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2 … U Platzbecker, JM Middeke, K Sockel, R Herbst, D Wolf, CD Baldus, ... The Lancet Oncology 19 (12), 1668-1679, 2018 | 314 | 2018 |
| Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial J Cortes, AE Perl, H Döhner, H Kantarjian, G Martinelli, T Kovacsovics, ... The Lancet Oncology 19 (7), 889-903, 2018 | 272 | 2018 |
| Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy H Döhner, M Lübbert, W Fiedler, L Fouillard, A Haaland, JM Brandwein, ... Blood, The Journal of the American Society of Hematology 124 (9), 1426-1433, 2014 | 263 | 2014 |
| Requirement for CDK6 in MLL-rearranged acute myeloid leukemia T Placke, K Faber, A Nonami, SL Putwain, HR Salih, FH Heidel, A Krämer, ... Blood, The Journal of the American Society of Hematology 124 (1), 13-23, 2014 | 219 | 2014 |
| Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen B Rebacz, TO Larsen, MH Clausen, MH Rønnest, H Löffler, AD Ho, ... Cancer research 67 (13), 6342-6350, 2007 | 216 | 2007 |
| Centrosome replication, genomic instability and cancer A Krämer, K Neben, AD Ho Leukemia 16 (5), 767-775, 2002 | 209 | 2002 |
| Aneuploidy correlated 100% with chemical transformation of Chinese hamster cells R Li, G Yerganian, P Duesberg, A Kraemer, A Willer, C Rausch, ... Proceedings of the National Academy of Sciences 94 (26), 14506-14511, 1997 | 209 | 1997 |
| Proteins required for centrosome clustering in cancer cells B Leber, B Maier, F Fuchs, J Chi, P Riffel, S Anderhub, L Wagner, AD Ho, ... Science translational medicine 2 (33), 33ra38-33ra38, 2010 | 204 | 2010 |
| STIL is required for centriole duplication in human cells J Vulprecht, A David, A Tibelius, A Castiel, G Konotop, F Liu, F Bestvater, ... Journal of cell science 125 (5), 1353-1362, 2012 | 203 | 2012 |
| Aneuploidy precedes and segregates with chemical carcinogenesis P Duesberg, R Li, D Rasnick, C Rausch, A Willer, A Kraemer, ... Cancer Genetics and Cytogenetics 119 (2), 83-93, 2000 | 173 | 2000 |
| Structure meets function—centrosomes, genome maintenance and the DNA damage response H Löffler, J Lukas, J Bartek, A Krämer Experimental cell research 312 (14), 2633-2640, 2006 | 146 | 2006 |
| Centrosome clustering and chromosomal (in) stability: a matter of life and death A Krämer, B Maier, J Bartek Molecular oncology 5 (4), 324-335, 2011 | 144 | 2011 |
| Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, ... Leukemia 31 (10), 2020-2028, 2017 | 141 | 2017 |
